ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 2, 2011, Pages 249-251

  Dougados, Maxime ^a   Simon, Paternotte ^a   Braun, Juergen ^b   Burgos Vargas, Ruben ^c   Maksymowych, Walter P ^d   Sieper, Joachim ^e   Van Der Heijde, Désirée ^f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d UNIVERSITY OF ALBERTA   (Canada)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; TENOXICAM;

ANKYLOSING SPONDYLITIS; ARTICLE; HUMAN; PRIORITY JOURNAL; SCORING SYSTEM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; RESEARCH DESIGN; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 78751696859     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.133488     Document Type: Article

References (29)

1. Sieper J, Haibel H, Mielants H. Management of spondyloarthritides. EULAR Compendium, JWJ Bijlsma. BMJ 2009;116-31.
2. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117-28.
3. Dougados M. Diagnosis and monitoring of spondylarthropathy. Compr Ther 1990;16:52-6.
4. Dougados M, Dijkmans B, Khan M, et al. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61 (Suppl 3):40-50.
5. Miceli-Richard C, Dougados M. NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002;20 (6 Suppl 28):S65-6.
6. Barkhuizen A, Steinfeld S, Robbins J, et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006;33:1805-12.
7. Dougados M, Béhier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
8. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15.
9. Dougados M, Gueguen A, Nakache JP, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal antiinflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
10. Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford) 2010;49:536-41.
11. Wanders A, Heijde D, LandewéR, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis:a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
12. Song IH, Poddubnyy DA, Rudwaleit M, et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008;58:929-38.
13. Straube S, Tramèr MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation:effects of time and NSAID use. BMC Gastroenterol 2009;9:41.
14. Boers M, Tangelder MJ, van Ingen H, et al. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007;66:417-18.
15. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-37.
16. Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009;27:2332-41.
17. Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 2007;16:762-72.
18. Scott PA, Kingsley GH, Smith CM, et al. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007;66:1296-304.
19. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006;31:565-76.
20. Singh G, Wu O, Langhorne P, et al. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8:R153.
21. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
22. Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006;119:552-9.
23. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
24. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997;157:1531-6.
25. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24.
26. AFSSAPS. Rappel des règles de bon usage des AINS. AFSSAPS, 2006.
27. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J (Clin Res Ed) 1986;293:911-14.
28. Constant F, Guillemin F, Herbeth B, et al. Measurement methods of drug consumption as a secondary judgment criterion for clinical trials in chronic rheumatic diseases. Am J Epidemiol 1997;145:826-33.
29. Dougados M, Kumar A, van der Heijde D, et al. Non-Steroidal Anti-Inflammatory Drug-Sparing Effect of Adalimumab Treatment in Patients with Ankylosing Spondylitis. EULAR Arthritis Rheum 2009, SAT0277 (Poster).